Oxford Biotherapeutics Limited

Early Stage

Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody-based medicines for oncology.  OBT's strategy is to develop innovative antibody-based cancer drugs, with integrated diagnositcs, against novel targets that it has discovered in its unique proteomic database.  Through its alliances with world leaders in antibody development (including Sanofi Aventis, GSK, Amgen, Seattle Genetics and Biowa) OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of first-in-class therapeutics for the treatment of cancer.  OBT's pipeline will deliver cost-effective medicines to fulfill the major unmet medical need of cancer patients.

OBT has a world leading database of oncology biomarkers and had begun to establish key strategic relationships that would be used to develop these novel targets.  There were also clear market drivers towards personalised medicine.

Our investment has supported the development of a substandial pipeline of novel targets, the assembly of a highly skilled leadership team and the achievement of key strategic collaborations and license agreements.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200